Haemonetics 3rd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website

Rhea-AI Summary

Haemonetics Corporation (HAE) has released its financial results for the third quarter of fiscal year 2024, ending on December 30, 2023. The company will host a conference call and webcast to discuss the results with investors and analysts.

Financial Analyst

The release of Haemonetics Corporation's third-quarter financial results is a pivotal moment for stakeholders to assess the company's performance and strategic direction. A critical analysis of the financials would focus on key metrics such as revenue growth, profit margins and cash flow. Revenue growth indicates market demand and operational scale, while profit margins reflect the efficiency of cost management. Cash flow is essential for understanding the company's liquidity and ability to fund operations and investments. Stakeholders should compare these metrics to previous quarters and industry benchmarks to gauge Haemonetics' market position and financial health.

Additionally, the third-quarter performance often sets the tone for year-end expectations. Investors should pay close attention to any forward-looking statements or guidance provided by the management during the conference call as these will influence market sentiment and stock valuation. Any significant deviation from industry norms or exceptional results should be scrutinized for underlying causes, such as one-time events or changes in market dynamics.

Market Research Analyst

From a market perspective, Haemonetics Corporation's financial results serve as an indicator of its competitive standing within the medical devices and blood management industry. Market share trends, customer acquisition rates and the performance of new products or services are crucial for understanding the company's growth trajectory. An analysis of these factors can reveal the effectiveness of Haemonetics' business strategies and its ability to innovate and adapt to market changes.

Furthermore, the response of the stock market to the financial release can provide insights into investor confidence and perceived value. Volatility in stock price following the release may indicate market consensus or disagreements with the company's reported performance and future prospects. It is also important to evaluate the impact of external factors such as regulatory changes, competitive actions and economic conditions on the company's performance.

Financial release accessible online

BOSTON, Feb. 8, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2024, which ended December 30, 2023, are available on its Investor Relations website.

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 8, 2024. The conference call and webcast can be accessed with the following information:

• Teleconference link: https://register.vevent.com/register/BIddeef4a5eb8d4c2d96bcf82386d2a73e 
• Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
• A live webcast of the call can be accessed on Haemonetics' investor relations website or via the following link: https://edge.media-server.com/mmc/p/unynzc8w

In addition, the Company has posted to its Investor Relations website the earnings release that will be referenced on its conference call and webcast, a link to which is available below. 

Direct link to 3Q FY24 Earnings Release:
https://haemonetics.gcs-web.com/static-files/7edda7ff-7ea8-4178-b828-abcfcbafec7c 

A replay of the conference call and webcast will be available for one year beginning on February 8, 2024, at 11:00 a.m. ET using the conference call webcast link provided in this press release.

ABOUT HAEMONETICS
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contacts:
Olga Guyette, Sr. Director-Investor Relations & Treasury	David Trenk, Manager-Investor Relations
(781) 356-9763	(203) 733-4987
olga.guyette@haemonetics.com	david.trenk@haemonetics.com
Media Contact:
Josh Gitelson, Director-Global Communications
(781) 356-9776
josh.gitelson@haemonetics.com

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-3rd-quarter-fiscal-year-2024-earnings-release-available-on-investor-relations-website-302056960.html

SOURCE Haemonetics Corporation

When did Haemonetics Corporation release its financial results for the third quarter of fiscal year 2024?

Haemonetics Corporation released its financial results for the third quarter of fiscal year 2024, which ended on December 30, 2023.

Where can I find Haemonetics Corporation's financial release for the third quarter of fiscal year 2024?

Haemonetics Corporation's financial release for the third quarter of fiscal year 2024 is accessible on its Investor Relations website.

What is the ticker symbol for Haemonetics Corporation?

The ticker symbol for Haemonetics Corporation is HAE.

What will the conference call and webcast with investors and analysts discuss?

The conference call and webcast will discuss and answer questions about the financial results for the third quarter of fiscal year 2024.